Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections

被引:88
|
作者
Obeid, Anthony [1 ]
Gao, Xinxiao [1 ,2 ]
Ali, Ferhina S. [1 ]
Talcott, Katherine E. [1 ]
Aderman, Christopher M. [1 ]
Hyman, Leslie [3 ]
Ho, Allen C. [1 ]
Hsu, Jason [1 ]
机构
[1] Wills Eye Hosp & Res Inst, Retina Serv, Mid Atlantic Retina, Philadelphia, PA USA
[2] Capital Med Univ, Beijing Anzhen Hosp, Beijing, Peoples R China
[3] Wills Eye Hosp & Res Inst, Vis Res Ctr, Philadelphia, PA USA
关键词
UNITED-STATES; MEDICARE BENEFICIARIES; EYE EXAMINATIONS; MACULAR EDEMA; DISTRUST; TRIAL; CARE;
D O I
10.1016/j.ophtha.2018.02.034
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Loss to follow-up (LTFU) may contribute to vision loss in patients with active proliferative diabetic retinopathy (PDR). The aim of this study is to determine and compare the rates of LTFU in patients with PDR receiving panretinal photocoagulation (PRP) or intravitreal injections (IVIs) with anti-vascular endothelial growth factor (VEGF) over approximately 4 years. Moreover, this study evaluates various risk factors for LTFU. Design: Retrospective cohort study. Participants: A total of 2302 patients with PDR receiving IVIs with anti-VEGF or PRP between January 1, 2012, and April 20, 2016. Methods: Intervals between each procedure and the subsequent follow-up visit were measured. Loss to follow-up was defined as at least 1 interval exceeding 12 months duration. Main Outcome Measures: The LTFU rates and associated risk factors. Results: A total of 1718 patients (74.6%) followed up postprocedure and 584 patients (25.4%) were LTFU over approximately 4 years. Of the patients receiving PRP, 28.0% were LTFU compared with 22.1% of patients receiving IVI with anti-VEGF (P = 0.001). The LTFU rates decreased as age increased, with rates of 28.1% for patients aged <= 55 years, 27.0% for patients aged 56 to 65 years, and 20.9% for patients aged >65 years (P = 0.002). Loss to follow-up also differed by race, with rates of 19.4% for whites, 30.2% for African Americans, 19.7% for Asians, 38.0% for Hispanics, Native Americans, and Pacific Islanders, and 34.9% for patients of unreported race (P < 0.001). The LTFU rates also increased as regional average adjusted gross incomes (AGIs) decreased, with rates of 33.9% for patients with regional average AGI of <=$40 000, 24.0% for patients with regional average AGI from $41 000 to $80 000, and 19.7% for patients with regional average AGI >$80 000 (P < 0.001). Procedure type, age, race, and regional average AGI were all significant (P < 0.05) independent risk factors of LTFU in the multivariate regression. Conclusions: A large proportion of patients with PDR were LTFU after receiving PRP or an anti-VEGF injection over approximately 4 years. Key risk factors included age, race, and regional average AGI. (C) 2018 by the American Academy of Ophthalmology
引用
收藏
页码:1386 / 1392
页数:7
相关论文
共 50 条
  • [1] Loss to Follow up in Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and/or Panretinal Photocoagulation in the United States
    Khurana, Rahul N.
    Wang, Jay C.
    Zhang, Sen
    Li, Charles
    Lum, Flora
    OPHTHALMOLOGY RETINA, 2024, 8 (10): : 953 - 961
  • [2] Outcomes of intravitreal anti-VEGF injections and panretinal photocoagulation in preretinal hemorrhage secondary to proliferative diabetic retinopathy involving the fovea
    Brar, Manpreet
    Sharma, Mansi
    Grewal, Satinder Pal Singh
    Dogra, Mangat
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2024, 72 (05) : 687 - 691
  • [3] Resident Perspective: Intravitreal anti-VEGF vs. panretinal laser photocoagulation for proliferative diabetic retinopathy
    Han, Sangsu
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2021, 56 (06): : E171 - E172
  • [4] Anti-VEGF Pharmacotherapy as an Alternative to Panretinal Laser Photocoagulation for Proliferative Diabetic Retinopathy
    Olsen, Timothy W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (20): : 2135 - 2136
  • [5] Anti-VEGF Therapy for Persistent Neovascularization after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy
    Mehanna, Carl-Joe
    Fattah, Maamoun Abdul
    Haddad, Sandra
    Tamim, Hani
    Ghazi, Nicola
    Salti, Haytham
    OPHTHALMOLOGY RETINA, 2019, 3 (06): : 473 - 477
  • [6] Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy
    Alsoudi, Amer F.
    Wai, Karen M.
    Koo, Euna
    Parikh, Ravi
    Mruthyunjaya, Prithvi
    Rahimy, Ehsan
    JAMA OPHTHALMOLOGY, 2024, 142 (10) : 972 - 975
  • [7] Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy-A Review
    Gawecki, Maciej
    Kicinski, Krzysztof
    Bianco, Lorenzo
    Parodi, Maurizio Battaglia
    DIAGNOSTICS, 2024, 14 (01)
  • [8] Loss to Follow-Up in Patients With Retinal Vein Occlusion Undergoing Intravitreal Anti-VEGF Injections
    Gao, Xinxiao
    Obeid, Anthony
    Adam, Murtaza K.
    Hyman, Leslie
    Ho, Allen C.
    Hsu, Jason
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2019, 50 (03): : 159 - 166
  • [9] Panretinal Photocoagulation Versus Intravitreal Injections in Proliferative Diabetic Retinopathy - The Best Way of Treatment
    Partyka, I.
    Czupryniak, L.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2018, 28 : 25 - 26
  • [10] Anti-VEGF Injections vs. Panretinal Photocoagulation Laser Therapy for Proliferative Diabetic Retinopathy A Systematic Review and Meta-Analysis
    Macaron, Marie-Michele
    Al Sabbakh, Nader
    Shami, M. Zaid
    Akrobetu, Dennis
    Bourdakos, Natalie E.
    Abdulsalam, Fatma A. M.
    Nakanishi, Hayato
    Than, Christian A.
    Bakri, Sophie J.
    OPHTHALMOLOGY RETINA, 2025, 9 (02): : 105 - 121